Metastatic Hormone Refractory Prostate Cancer Terminated Phase 3 Trials for Risedronic acid (DB00884)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Terminated3 IdentifierTitlePurposeDrugs
NCT00216060Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal TherapyPrevention